(Q30580118)

25 June 2017

1 reference

title

Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment (English)

1 reference

25 June 2017

Rudick RA

1

1 reference

25 June 2017

Goodman A

series ordinal

2

1 reference

25 June 2017

Herndon RM

series ordinal

3

1 reference

25 June 2017

Panitch HS

series ordinal

4

1 reference

25 June 2017

publication date

1 July 1999

1 reference

Journal of Neuroimmunology

25 June 2017

published in

1 reference

25 June 2017

volume

98

1 reference

25 June 2017

issue

1

1 reference

25 June 2017

page(s)

22-28

1 reference

Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

High resolution proton NMR spectroscopy of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Axonal damage in acute multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

1H MRSI of normal appearing white matter in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Prediction of outcome in multiple sclerosis based on multivariate models

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

Natural history of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900077-6

7 January 2021

10.1016/S0165-5728(99)00077-6

Identifiers

DOI

1 reference

25 June 2017

1 reference